Cancer Vaccines (Industry News)

Liposome Technology Shows Promise in Dendritic Cell Therapy for Cancer

Published in Blood Weekly, January 13th, 2000

Data on laboratory maturation of dendritic cells using the liposomal encapsulated MUC1 produced by Biomira, Inc., were presented at the American Association of Blood Banks Meeting held in San Francisco, California, November 6-10, 1999, by the Scottish National Blood Transfusion Services Cell Therapy Group.

In 1998, Biomira, Inc., reported that potent primary anti-MUC1 T-cell responses could be generated in vitro following incubation of normal human antigen presenting cells (APCs) with BLP25 liposomes followed by the addition of autologous T cells to the culture.

More recent data presented at the Society for Biological Therapy Annual Meeting in Boston...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-01-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry